ANI Pharmaceuticals

In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for ANI's rapidly expanding research and development program. With several ANDAs pending FDA approval, and in various stages of development, ANI is poised for tremendous growth in the months and years to come!
Type
Public
HQ
Baudette, US
Size (employees)
143 (est)+33%
ANI Pharmaceuticals is headquartered in Baudette, US

ANI Pharmaceuticals Office Locations

ANI Pharmaceuticals has an office in Baudette
Baudette, US (HQ)
210 Main St W
Baudette, US
455 Idc Rd SW

ANI Pharmaceuticals Metrics

ANI Pharmaceuticals Financial Metrics

Revenue (2016)

$128.6 m

Revenue growth (2015-16), %

69%

Gross profit

$79.8 m

Gross profit margin (2016), %

62%

Net income (2016)

$3.9 m

Market capitalization (21-Mar-2017)

$521.5 m

Closing share price (21-Mar-2017)

$45.3

Cash (31-Dec-2016)

$27.4 m
ANI Pharmaceuticals's current market capitalization is $521.5 m.
ANI Pharmaceuticals's revenue was reported to be $128.6 m in FY, 2016 which is a 68.5% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$30.1 m$56 m$76.3 m$128.6 m

Revenue growth, %

86%36%69%

Cost of goods sold

$10 m$11.5 m$12.7 m$48.8 m

Gross profit

$20.1 m$44.5 m$63.6 m$79.8 m

Gross profit Margin, %

67%80%83%62%

Operating expense total

$19.2 m$24.5 m$30.9 m$108.5 m

EBIT

$898 k$20 m$32.7 m$20.1 m

EBIT margin, %

3%36%43%16%

Interest expense

$467 k$787 k$11 m$11.3 m

Net Income

$301 k$28.7 m$15.4 m$3.9 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$11.1 m$169 m$154.7 m$27.4 m

Accounts Receivable

Inventories

$2 m$1.5 m$3.6 m

Current Assets

$27.7 m$203.5 m$192.6 m$103 m

PP&E

$4.5 m$5.2 m$7.1 m$11 m

Goodwill

$1.8 m$1.8 m$1.8 m$1.8 m

Total Assets

$44.5 m$263.7 m$285.3 m$322.9 m

Accounts Payable

$1.4 m$2.7 m$2.1 m$3.4 m

Current Liabilities

$3.5 m$13.2 m$11.8 m$31.9 m

Additional Paid-in Capital

$89.5 m$159.5 m$164.4 m$172.6 m

Retained Earnings

($48.5 m)($19.7 m)($4.4 m)($2.9 m)

Total Equity

$139.8 m$160.1 m$169.6 m

Financial Leverage

1.9 x1.8 x1.9 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$301 k$28.7 m$15.4 m$3.9 m

Depreciation and Amortization

$1.1 m$3.9 m$6.9 m$22.3 m

Accounts Receivable

($7.1 m)($4.8 m)($4.6 m)($24 m)

Inventories

($708 k)($3.5 m)($314 k)($647 k)

Accounts Payable

($565 k)$225 k($1 m)$1.1 m

Cash From Operating Activities

$11.1 m$157.9 m($14.4 m)$27.5 m

Purchases of PP&E

($191 k)($1.1 m)($2.2 m)($4.6 m)

Cash From Investing Activities

($154.1 m)

Interest Paid

$250 k$4.2 m

Income Taxes Paid

$147 k$13.3 m$9.5 m

ANI Pharmaceuticals Market Value History

ANI Pharmaceuticals Company Life

You may also be interested in